vs
德康医疗（DXCM）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是德康医疗的1.2倍（$1.5B vs $1.3B），德康医疗净利率更高（21.2% vs 12.9%，领先8.3%），德康医疗同比增速更快（21.6% vs 9.2%），过去两年Steris的营收复合增速更高（15.8% vs 12.0%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
DXCM vs STE — 直观对比
营收规模更大
STE
是对方的1.2倍
$1.3B
营收增速更快
DXCM
高出12.4%
9.2%
净利率更高
DXCM
高出8.3%
12.9%
两年增速更快
STE
近两年复合增速
12.0%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.5B |
| 净利润 | $267.3M | $192.9M |
| 毛利率 | 62.9% | 43.8% |
| 营业利润率 | 25.6% | 18.3% |
| 净利率 | 21.2% | 12.9% |
| 营收同比 | 21.6% | 9.2% |
| 净利润同比 | 153.6% | 11.2% |
| 每股收益（稀释后） | $0.67 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMSTE
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.2B | $1.5B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.0B | $1.5B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $994.2M | $1.3B | ||
| Q2 24 | $1.0B | $1.3B |
净利润DXCMSTE
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $192.9M | ||
| Q3 25 | $283.8M | $191.9M | ||
| Q2 25 | $179.8M | $177.4M | ||
| Q1 25 | $105.4M | $145.7M | ||
| Q4 24 | $151.7M | $173.5M | ||
| Q3 24 | $134.6M | $150.0M | ||
| Q2 24 | $143.5M | $145.4M |
毛利率DXCMSTE
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | 43.8% | ||
| Q3 25 | 60.5% | 44.2% | ||
| Q2 25 | 59.5% | 45.1% | ||
| Q1 25 | 56.9% | 43.3% | ||
| Q4 24 | 58.9% | 44.5% | ||
| Q3 24 | 59.7% | 43.6% | ||
| Q2 24 | 62.4% | 44.7% |
营业利润率DXCMSTE
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 18.3% | ||
| Q3 25 | 20.1% | 18.2% | ||
| Q2 25 | 18.4% | 17.7% | ||
| Q1 25 | 12.9% | 14.6% | ||
| Q4 24 | 17.0% | 17.9% | ||
| Q3 24 | 15.3% | 16.5% | ||
| Q2 24 | 15.7% | 14.5% |
净利率DXCMSTE
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 12.9% | ||
| Q3 25 | 23.5% | 13.1% | ||
| Q2 25 | 15.5% | 12.8% | ||
| Q1 25 | 10.2% | 9.8% | ||
| Q4 24 | 13.6% | 12.7% | ||
| Q3 24 | 13.5% | 11.3% | ||
| Q2 24 | 14.3% | 11.4% |
每股收益（稀释后）DXCMSTE
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $1.96 | ||
| Q3 25 | $0.70 | $1.94 | ||
| Q2 25 | $0.45 | $1.79 | ||
| Q1 25 | $0.27 | $1.48 | ||
| Q4 24 | $0.37 | $1.75 | ||
| Q3 24 | $0.34 | $1.51 | ||
| Q2 24 | $0.35 | $1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $2.7B | $7.2B |
| 总资产 | $6.3B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资DXCMSTE
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $423.7M | ||
| Q3 25 | $1.8B | $319.2M | ||
| Q2 25 | $1.2B | $279.7M | ||
| Q1 25 | $904.9M | $171.7M | ||
| Q4 24 | $606.1M | $155.2M | ||
| Q3 24 | $621.2M | $172.2M | ||
| Q2 24 | $939.2M | $198.3M |
总债务DXCMSTE
| Q1 26 | — | — | ||
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
股东权益DXCMSTE
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $7.2B | ||
| Q3 25 | $2.7B | $7.0B | ||
| Q2 25 | $2.6B | $7.0B | ||
| Q1 25 | $2.3B | $6.6B | ||
| Q4 24 | $2.1B | $6.4B | ||
| Q3 24 | $2.0B | $6.6B | ||
| Q2 24 | $2.4B | $6.4B |
总资产DXCMSTE
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $10.6B | ||
| Q3 25 | $7.5B | $10.4B | ||
| Q2 25 | $7.3B | $10.4B | ||
| Q1 25 | $6.8B | $10.1B | ||
| Q4 24 | $6.5B | $10.0B | ||
| Q3 24 | $6.4B | $10.2B | ||
| Q2 24 | $6.8B | $10.1B |
负债/权益比DXCMSTE
| Q1 26 | — | — | ||
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $298.2M |
| 自由现金流经营现金流 - 资本支出 | — | $199.5M |
| 自由现金流率自由现金流/营收 | — | 13.3% |
| 资本支出强度资本支出/营收 | — | 6.6% |
| 现金转化率经营现金流/净利润 | — | 1.55× |
| 过去12个月自由现金流最近4个季度 | — | $917.1M |
8季度趋势，按日历期对齐
经营现金流DXCMSTE
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $298.2M | ||
| Q3 25 | $659.9M | $287.8M | ||
| Q2 25 | $303.0M | $420.0M | ||
| Q1 25 | $183.8M | $260.8M | ||
| Q4 24 | $301.4M | $332.8M | ||
| Q3 24 | $199.5M | $250.7M | ||
| Q2 24 | $279.4M | $303.7M |
自由现金流DXCMSTE
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | $199.5M | ||
| Q3 25 | $579.4M | $201.3M | ||
| Q2 25 | $208.9M | $326.4M | ||
| Q1 25 | $96.8M | $189.9M | ||
| Q4 24 | $176.8M | $243.6M | ||
| Q3 24 | $88.3M | $148.8M | ||
| Q2 24 | $213.3M | $195.7M |
自由现金流率DXCMSTE
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 13.3% | ||
| Q3 25 | 47.9% | 13.8% | ||
| Q2 25 | 18.1% | 23.5% | ||
| Q1 25 | 9.3% | 12.8% | ||
| Q4 24 | 15.9% | 17.8% | ||
| Q3 24 | 8.9% | 11.2% | ||
| Q2 24 | 21.2% | 15.3% |
资本支出强度DXCMSTE
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 6.6% | ||
| Q3 25 | 6.7% | 5.9% | ||
| Q2 25 | 8.1% | 6.7% | ||
| Q1 25 | 8.4% | 4.8% | ||
| Q4 24 | 11.2% | 6.5% | ||
| Q3 24 | 11.2% | 7.7% | ||
| Q2 24 | 6.6% | 8.4% |
现金转化率DXCMSTE
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.55× | ||
| Q3 25 | 2.33× | 1.50× | ||
| Q2 25 | 1.69× | 2.37× | ||
| Q1 25 | 1.74× | 1.79× | ||
| Q4 24 | 1.99× | 1.92× | ||
| Q3 24 | 1.48× | 1.67× | ||
| Q2 24 | 1.95× | 2.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
